Saturday 17 October 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024. In the quarter to June 2026, revenue fell 1.91%, EPS was flat, free cash flow fell 31.0% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.73
0.23
−11.73%
Follow PACB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.49 | 3.51 | 2.52 | 3.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.58) | (29.42) | (9.03) | (14.67) | |
P/B ratio |
10.67 | 104.86 | 170.60 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.73 | 5.79 | 4.83 | 5.83 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.96) | (8.33) | (6.91) | (7.87) | |
EV/FCF |
(5.56) | (7.79) | (10.86) | (11.55) | |
Quick Ratio |
5.21 | 4.32 | 4.67 | 3.90 | |
Current Ratio |
6.24 | 5.15 | 5.65 | 4.92 | |
Net Debt/EBITDA |
(9.78) | (9.89) | 60.22 | (10.11) | |
Debt/Assets |
80.33% | 82.31% | 0.00% | 85.70% | |
Debt/Equity |
17.88 | 120.65 | 0.00 | (19.40) | |
Asset Turnover |
0.14 | 0.16 | 0.19 | 0.20 | |
Operating CF/Net income |
0.49 | 0.47 | 5.40 | 0.80 | |
Capex/Depreciation |
0.02 | (0.21) | 11.12 | (0.84) | |
Interest Coverage |
(22.36) | (23.68) | (4.80) | (21.14) | |
Research and Development Expense of Revenue |
59.43% | 51.25% | 52.74% | 59.02% | |
Selling, General and Administrative Expense of Revenue |
80.90% | 76.27% | 83.79% | 85.61% | |
Intangible Assets out of Total Assets |
0.42 | 0.42 | 0.42 | 0.44 | |
Share Based Compensation of Revenue |
28.57% | 21.48% | 11.99% | 23.75% | |
Graham Net Nets |
(0.97) | (0.72) | (1.02) | (0.86) | |
Graham Number |
0.00 | 0.00 | 0.00 | 1.02 | |
Earnings Yield |
(132.81%) | (98.40%) | (32.58%) | (25.60%) | |
Free Cash Flow Yield |
(34.13%) | (21.20%) | (17.64%) | (15.42%) | |
Revenue per Share |
0.13 | 0.15 | 0.12 | 0.13 | |
Operating CF per Share |
(0.06) | (0.06) | (0.15) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.14 | (0.01) | |
Free Cash Flow per Share |
(0.06) | (0.07) | (0.01) | (0.13) | |
Cash per Share |
0.99 | 0.93 | 0.90 | 0.76 | |
Shareholders Equity per Share |
0.12 | 0.02 | 0.01 | (0.11) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.12 | 0.02 | 0.01 | (0.11) | |
Free Cash Flow |
(18.62) | (19.93) | (2.73) | (39.19) | |
Working Capital |
331.03 | 302.22 | 304.16 | 269.83 | |
Capital Expenditures |
0.09 | (0.86) | 41.96 | (3.61) | |
Net Current Asset Value |
(372.83) | (403.68) | (410.48) | (446.42) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | (1.13) | 0.09 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
30.00 | 31.49 | 30.50 | 31.68 | |
Average Payables |
14.21 | 18.68 | 13.82 | 17.14 | |
Average Inventory |
59.45 | 54.02 | 52.51 | 57.46 | |
Average Assets |
1,126.61 | 1,022.27 | 821.58 | 788.66 | |
Average Common Equity |
244.61 | 255.97 | 47.00 | 14.14 |
Columns are period end dates